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A chemoresponse assay for prediction of platinum resistance
in primary ovarian cancer
Thomas C. Krivak, MD; Shashikant Lele, MD; Scott Richard, MD; Angeles Alvarez Secord, MD; Charles A. Leath III, MD;
Stacey L. Brower, PhD; Chunqiao Tian, PhD; Richard G. Moore, MD
OBJECTIVE: Recurrence following primary platinum-based chemo- nonresistant (sensitive þ IS) tumors (median PFS: 11.8 vs 16.6
therapy remains a challenge in the treatment of patients with
advanced-stage epithelial ovarian cancer. This study examines
whether a chemoresponse assay can identify patients who are
platinum-resistant prior to treatment.
STUDY DESIGN: Women (n ¼ 276) with International Federation of
Gynecology and Obstetrics stage III-IV ovarian, fallopian, and perito-
neal cancer were enrolled in an observational study, and the
responsiveness of their tumors was evaluated using a chemoresponse
assay. All patients were treated with a platinum/taxane regimen
following cytoreductive surgery. Assay responses to carboplatin or
paclitaxel were classified as sensitive, intermediate sensitive (IS), or
resistant. Association of assay response with progression-free survival
(PFS) was analyzed using the Kaplan-Meier method and a Cox
regression model.
RESULTS: Patients whose tumors were resistant to carboplatin were at
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Open access under CC BY-NC-ND license.months, respectively, P < .001), and the association was confirmed
after adjusting for other clinical factors (hazard ratio, 1.71; 95%
confidence interval, 1.12e2.62; P ¼ .013). Association of assay
response to paclitaxel with PFS trended in multivariate analysis (hazard
ratio, 1.28; 95% confidence interval, 0.84e1.95; P ¼ .245). For
tumors resistant to carboplatin, 59% were sensitive or IS to at least 1
other commonly used agent, demonstrating the ability of the assay to
inform treatment decisions beyond the standard platinum/taxane
regimen.
CONCLUSION: Assay resistance to carboplatin is strongly associated
with shortened PFS among advanced-stage epithelial ovarian cancer
patients treated with carboplatin þ paclitaxel therapy, supporting use
of this assay to identify patients likely to experience early recurrence on
standard platinum-based therapy.
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2014;211:68.e1-8.n 2013, it was estimated that thereI will be 22,240 new cases of ovarian
cancer and 14,030 deaths due to this
disease in the United States; epithelial
ovarian cancer (EOC) represents the
leading cause of death from gynecologic
malignancies.1 The poor prognosisobserved with EOC is largely attributed
to late detection of the disease (ie, once it
has already advanced to late stages), as
well as intrinsic drug refractory and/or
emerging drug resistance to initial
chemotherapy. Evidence from random-
ized clinical trials has established theynecology, Magee-Wom
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as standard ﬁrst-line chemotherapy
for patients with advanced-stage EOC,
yielding response rates of 60-70%.2,3
However, most such patients experi-
ence relapse within 1-2 years, and only
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www.AJOG.org Oncology Researcha heterogeneous disease, and a platinum/
taxane combination is not the optimal
chemotherapy regimen for all patients.
Efforts have been taken to improve
toxicities, response rates, and survival
through the use of alternate chemother-
apies, the use of different treatment
schedules, or the incorporation of bio-
logic agents, with encouraging data
recently reported for the latter 2 ap-
proaches.5-7 Over the last 2 decades,
multiple clinical studies have attempted
to identify chemotherapy regimens su-
perior to platinum/taxane in theﬁrst-line
treatment of advanced-stage EOC.3,8-10
Although progression-free survival
(PFS) and overall survival (OS) observed
in these alternate regimens are no better
(and, inmany studies, are noworse) than
those observed with the platinum/taxane
standard, the alternate regimens may be
considered to be equivalent in clinical
practice.
In EOC, clinically useful markers that
identify platinum-resistant tumors,
among the overall high number of che-
mosensitive patients, remain a critical
need. If identiﬁed early, platinum-
resistant EOC patients could beneﬁt
from alternate and/or additional thera-
peutic options in ﬁrst-line therapy.
Moreover, reliable early identiﬁcation of
platinum resistance may allow the
development of clinical trials speciﬁcally
targeting this population with novel
alternate therapies.
Chemoresponse assays have been
investigated as a method for individual-
izing chemotherapy treatment decisions
and improving outcomes in cancer pa-
tients. Recently, a prospective study
demonstrated that women with persis-
tent or recurrent EOC who were treated
with an assay-sensitive therapy experi-
enced signiﬁcantly improved PFS andOS
compared to those treated with assay-
resistant therapies.11 To further evaluate
the clinical relevance of this assay in the
primary setting, and in accordance with
standards for the reporting of diagnostic
accuracy criteria,12 an observational
study was conducted among women
with stage III/IV EOC treated by
standard-of-care chemotherapy. The
primary objective of this study is to
determine whether assay response tocarboplatin or/and paclitaxel is associ-
ated with disease progression among
patients with primary EOC following
initial treatment with platinum/taxane
regimen. Furthermore, this study will
evaluate whether this assay can be used to
identify patients who are resistant to
platinum-based treatment and at high
risk of early progression.
MATERIALS AND METHODS
Study population
Participants were prospectively enrolled
in an observational study of women with
gynecologic cancers. Tumor samples
from 54 institutions were submitted
for chemoresponse testing from 2006
through 2010.Womenwith International
Federation of Gynecology and Obstetrics
stage III-IV EOC, fallopian tube cancer,
and peritoneal cancer treated with
carboplatin/paclitaxel-based chemothe-
rapy following initial cytoreductive sur-
gery were included in the study. Patients
with a time interval of >2 months be-
tween surgery and initiation of chemo-
therapy, chemotherapy duration >6
months, and/or treatment consisting of
>10 cycles of chemotherapy were
excluded. The institutional review board
at each participating center approved this
study, and documented informed con-
sent was obtained from all enrolled
patients.
Chemoresponse assay
Details regarding the chemoresponse
assay employed in this study (ChemoFx;
Precision Therapeutics Inc, Pittsburgh,
PA) have been described elsewhere.13
Brieﬂy, the inhibition of tumor growth
wasmeasured at different concentrations
of each therapy. The survival fraction of
tumor cells at each concentration was
calculated as compared to a control (no
drug). The summation of survival frac-
tion values over 7 concentrations was
computed as the drug response score,
which represents the area under the dose-
response curve (AUC). A smaller AUC
score indicates greater sensitivity to the
therapy. Chemoresponse is classiﬁed into
1 of 3 categories according to the AUC
score: sensitive, intermediate sensitive
(IS), or resistant. The classiﬁcation cri-
terion was deﬁned based on theJULY 2014 Amedistribution of AUC scores among an
external population of patients with pri-
mary EOC. Speciﬁcally, the distributions
of AUC scores for carboplatin and pacli-
taxel were established based on referent
specimens. Scores ranked at the 25th and
75th percentiles were obtained. A tumor
with an AUC score <25th rank was
classiﬁed as sensitive, between 25th-75th
rank as IS, and >75th rank as resistant.Statistical analysis
The primary endpoint of this study was
PFS, calculated from the start of chemo-
therapy administration until the date of
ﬁrst documented disease recurrence,
death, or most recent follow-up. Com-
monly utilized patient prognostic infor-
mation was also collected, including: age,
Eastern Cooperative Oncology Group
performance status, histology, tumor
grade, stage, debulking status, and type of
chemotherapy administered. The physi-
cian(s) at each institution reported all
clinical information, which was quality
controlled according to a comprehensive
monitoring plan. Disease progression was
determined by clinical evidence, radio-
logical examination, and/or cancer
antigen 125. Optimal debulking was
deﬁned as residual tumor of 1 cm in
maximal dimension at the end of surgery
and was reported by enrolling physicians.
PFS based on assay response was esti-
mated using the Kaplan-Meier method,
and the log rank test was used to compare
the differences among sensitive, IS, and
resistant patients. Since the primary
objective of the current study was to
identify platinum-resistant patients, sen-
sitive and IS groups were combined for
further analyses. The association of the
assay and PFSwas also assessed using Cox
regression model adjusted for clinical
covariates (age, performance status [1-3 vs
0], histology [high-grade serous vs non-
high-grade serous], and stage/debulking
status [III-suboptimal/IVvs III-optimal]).
The hazard ratio (HR) of disease pro-
gression for patients treated with resistant
vs nonresistant (sensitive þ IS) therapy
was estimated. Subgroup analyses strati-
ﬁed by age group, performance status,
histology/tumor grade, or stage/debulking
status were also conducted.rican Journal of Obstetrics& Gynecology 68.e2
FIGURE 1
CONSORT diagram
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Patients
A total of 462 patients were enrolled in
this study, with 276 evaluable for inclu-
sion in the analysis (Figure 1). Patient
characteristics are displayed in Table 1.
The median age of the study population
was 61 years, and most patients had tu-
mors that were classiﬁed as papillary se-
rous (84%), poorly differentiated (83%),
stage III (85%), and optimally debulked
(72%) (Table 1). The majority (94%)
completed 4-8 cycles of chemotherapy.
The median follow-up period was 23
months (range, 12e37months), and 193
(70%) patients experienced disease pro-
gression within this time frame. The
median PFS was estimated to be 15.9
months (95% conﬁdence interval [CI],
14.3e17.1 months).Flow diagram describing exclusion criteria and their effect on total number of evaluable patients in
study.
C, carboplatin; CONSORT, Consolidated Standards of Reporting Trials; P, paclitaxel; PFS, progression-free survival.
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outcomes
Assay results for carboplatin were avail-
able for 231 patients, with 44 (19.1%)
patients identiﬁed as resistant to this
therapy in the chemoresponse assay.
Assay data for paclitaxel were available
for 226 patients, 49 (21.7%) of whom
were classiﬁed as resistant. Assay resis-
tance by age, performance status, his-
tology/grade, and stage/debulking status
is summarized in Table 2. There is no
evidence that assay result for either car-
boplatin or paclitaxel is correlated with
patient characteristics. Assay result for
carboplatin was signiﬁcantly associated
with clinical outcome (Figure 2). The
median PFS was 16.6 and 11.8 months
for assay nonresistant (sensitive þ IS)
and resistant tumors, respectively. Pa-
tients displaying assay resistance to car-
boplatin were at a higher risk of disease
progression as compared to those who
were nonresistant (HR, 1.87; 95% CI,
1.29e2.70; P< .001). These results were
consistent in multivariate analysis after
controlling for clinical covariates (HR,
1.71; 95% CI, 1.12e2.62; P ¼ .013)
(Table 3). Analysis of subgroups (age
group, performance status, histology,
stage/debulking status) was also con-
ducted (Figure 3), and the association
between PFS and assay result for
carboplatin was suggested across all68.e3 American Journal of Obstetrics& Gynecology JULY 2014
TABLE 1
Patient characteristics
(n[ 276)
Characteristic No. patients %
Age, y
Median (range) 61 (30e85)
<50 40 (14.5)
50e59 78 (28.3)
60e69 97 (35.1)
70 61 (22.1)
ECOG PS
0 144 (52.2)
1 63 (23.8)
2 11 (4.0)
3 2 (0.7)
Unknown 56 (20.3)
Tumor site
Ovarian 229 (83.0)
Peritoneal 32 (11.6)
Fallopian tube 15 (5.4)
Histology
Serous 232 (84.1)
Endometrioid 8 (2.9)
Clear cell 6 (2.2)
Mucinous 3 (1.1)
Others 27 (9.8)
Tumor grade
1 12 (4.4)
2 25 (9.1)
3 228 (82.6)
Unknown 11 (4.0)
Stage
III 234 (84.8)
IV 42 (15.2)
Debulking
Microscopic 64 (23.2)
Optimal 135 (48.9)
Suboptimal 59 (21.4)
Unknown 18 (6.5)
ECOG, Eastern Cooperative Oncology Group; PS, per-
formance status.
Krivak. Chemoresponse assay for platinum resis-
tance. Am J Obstet Gynecol 2014.
TABLE 2
Assay resistance by patient characteristics
Characteristic
Carboplatin Paclitaxel
No.
patients
No. resistant,
n (%) P value
No.
patients
No. resistant,
n (%) P value
Age group, y .987 .213
<60 100 19 (19.0) 96 17 (17.1)
60 131 25 (19.1) 130 32 (24.6)
ECOG PS .636 .526
0 126 24 (19.1) 120 25 (20.8)
1 59 13 (22.0) 60 15 (25.0)
Tumor grade .342 .438
1-2 32 8 (25.0) 30 5 (16.7)
3 190 34 (17.9) 187 43 (23.0)
HGS .204 .270
Yes 165 28 (17.0) 161 38 (23.6)
No 66 16 (24.2) 65 11 (16.9)
Stage/debulking .145 .136
III-Optimal 143 24 (16.8) 139 27 (19.4)
III-Suboptimal/IV 76 19 (25.0) 74 21 (28.4)
All 231 44 (19.1) 226 49 (21.7)
ECOG, Eastern Cooperative Oncology Group; HGS, high-grade (grade-3) serous; PS, performance status.
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patients with assay resistance to pacli-
taxel would experience shortened PFS,
but the association did not reach the
level of statistical signiﬁcance (Table 3).
Assay results for carboplatin and pacli-
taxel were highly correlated. For 220
patients with assay data available for both
agents, 75.5% were nonresistant to both
agents and 15.9% were resistant to
both agents, while only 8.6% of patients
were resistant to only 1 agent (5.9% to
carboplatin and 2.7% to paclitaxel). Pa-
tients resistant to both agents experienced
the worst outcomes (HR, 1.66; 95% CI,
1.10e2.52; P ¼ .017, as compared to pa-
tients nonresistant to both agents).
Multivariate analysis indicated the same
tendency, although the association was
not statistically signiﬁcant (Table 3).
Pattern of assay response
To estimate the proportion of patients
who may beneﬁt from assay-informedJULY 2014 Ametherapy, the assay responses to 7 clini-
cally relevant single agents (carboplatin,
cisplatin, gemcitabine, pegylated lipo-
somal doxorubicin, paclitaxel, doce-
taxel, and topotecan) were analyzed for
153 patients who had complete assay
data for all 7 of these agents (Figure 4).
Only 7% of the patients displayed assay
resistance to all 7 agents, while 5% were
sensitive to all 7 agents. Thus, 93% of
the patients were nonresistant (sensitive
or IS) to at least 1 agent. Speciﬁcally,
35% were IS to at least 1 agent, and
58% were sensitive to at least 1 agent.
Of note, 18% of these tumors were
resistant to carboplatin but, of those,
59% of them were nonresistant (sensi-
tive or IS) to at least 1 other agent in
the chemoresponse assay.
COMMENT
The standard of care for ﬁrst-line treat-
ment of patients with advanced-stage
EOC consists of aggressive cytoreductiverican Journal of Obstetrics& Gynecology 68.e4
FIGURE 2
Kaplan-Meier survival curves
Progression-free survival (PFS) in advanced-stage epithelial ovarian cancer patients receiving first-
line carboplatin/paclitaxel-based chemotherapy and exhibiting resistant (R) vs nonresistant (sensitive
[S] þ intermediate sensitive [I]) chemoresponse assay results for carboplatin.
CI, confidence interval; HR, hazard ratio.
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TABLE 3
Univariate and multivariate analyses of factors affecting disease
progression-free survival
Assay result
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI)a P value
Assay for carboplatin
Sensitiveb Referent Referent
Resistant 1.87 (1.29e2.70) < .001 1.71 (1.12e2.62) .013
Assay for paclitaxel
Sensitive Referent Referent
Resistant 1.43 (0.99e2.06) .055 1.28 (0.84e1.95) .245
Assay for carboplatin
and paclitaxel
Sensitive to both Referent Referent
Resistant to one 1.42 (0.83e2.43) .206 1.38 (0.76e2.51) .297
Resistant to both 1.66 (1.10e2.52) .017 1.51 (0.94e2.42) .090
CI, confidence interval; HR, hazard ratio.
a HR for disease progression estimated from Cox model adjusted for age, Eastern Cooperative Oncology Group performance
status, tumor grade/histology, and stage/debulking status; b Sensitive or intermediate sensitive assay result.
Krivak. Chemoresponse assay for platinum resistance. Am J Obstet Gynecol 2014.
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based chemotherapy14; however, in this
treatment approach, approximately 20-
30% of patients will have platinum-
resistant disease.15 If identiﬁed early,
platinum-resistant EOC patients may
beneﬁt from alternate and/or additional
therapeutic options in ﬁrst-line therapy.
At the time of recurrence, clinicians will
classify patients as being platinum sensi-
tive (EOC relapsing>6 months after the
end of ﬁrst-line chemotherapy) or plat-
inum resistant (EOC relapsing within 6
months after the end of ﬁrst-line
chemotherapy).16,17 This platinum sta-
tus classiﬁcation is the primary covariate
used in determining future prognosis and
subsequent treatment strategies. How-
ever, as with most clinical covariates, its
accuracy is not absolute; additional
measures of platinum responsiveness
may be beneﬁcial in further personalizing
treatment strategies. Using the current
standard clinical approach, identiﬁcation
of platinum-resistant disease is delayed
until after the patient has already expe-
rienced the costs and toxicities associated
with ﬁrst-line therapy. Earlier identiﬁca-
tion of effective ﬁrst-line treatment may
improve the disease course in EOC pa-
tients, potentially allowing them to
demonstrate response, avoid recurrence
for a longer time, and delay the onset of
decline in overall health, thereby allowing
more therapies to be given that may
further extend OS.
Unfortunately, molecular character-
ization of EOC has not yet been able to
substitute for the clinically observed
platinum status classiﬁcation. The cur-
rent study evaluates the potential utility
of a chemoresponse assay in identifying
platinum resistance in advanced-stage
EOC patients undergoing standard
ﬁrst-line treatment. Determining plat-
inum status earlier in the treatment of
advanced-stage EOC may prevent this
high-risk group of patients from being
exposed to multiple cycles of ineffective
therapy and allow for more effective
alternate therapeutic options earlier in
the disease, with the ultimate goal of
improving patient outcomes.
The results reported herein suggest
that the chemoresponse assay is an in-
dependent factor in identifying platinum
FIGURE 3
Subgroup analysis of association between assay results and
progression-free survival
Hazard ratios (HR) (resistant vs nonresistant) estimated for each subgroup of patients stratified by
major clinical covariates.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HGS, high-grade serous; PS, performance status.
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tients treated with standard ﬁrst-line
therapy (carboplatin/paclitaxel). Pa-
tients whose tumors were assay-resistant
to carboplatin had an increased risk of
early disease progression, as compared to
those whose assay results were nonre-
sistant for carboplatin, recurring on
average 5 months sooner. Furthermore,
based on the Kaplan-Meier plot of the
current study (Figure 2), within 6
months of the start of chemotherapy,
25% of assay-resistant patients had
already recurred, while <10% of assay-
sensitive (nonresistant) had recurred.
Likewise, at 18 months after the start of
chemotherapy, approximately 50% of
assay-sensitive patients had been free
of disease progression, while 80% of
assay-resistant patients had recurred.
Multivariate analysis of assay results
for paclitaxel demonstrated a positive
trend, and, further, patients who wereresistant to both agents demonstrated
the worst outcomes, which was signiﬁ-
cantly different from patients nonresis-
tant to both agents. These results are
consistent with the notion that the
platinum portion of the standard
regimen for advanced-stage EOC plays
the larger role in the clinical perfor-
mance of that regimen.18,19 As such, it is
expected that assay results for paclitaxel
are not as highly correlated with PFS as
are those for carboplatin and carbo-
platin þ paclitaxel. OS will be included
in future analyses.
The ability of this assay to identify
patients likely to be platinum resistant
creates the opportunity to consider
alternate treatments regimens for these
patients earlier in the course of treatment.
Alternate treatments may be considered
either initially following surgery or upon
ﬁrst clinical indication of suboptimal
performance during standard ﬁrst-lineJULY 2014 Ametreatment. Earlier intervention may
allow for a reduction in toxicities
incurred by the patient from ineffective
therapy, as well as a reduction in the
overall costs of treatment.20 Most
importantly, assay-informed treatment
decisions may lead to earlier treatment
with a more effective therapy, thereby
delaying recurrence and potentially
lengthening the overall expected survival
duration for these high-risk patients.
Identiﬁcation of advanced-stage EOC
patients as platinum resistant prior to
treatment could inform ﬁrst-line treat-
ment decisions in a variety of ways,
including substitution of alternate active
agents, alteration of the planned ﬁrst-line
therapy to a dose-dense approach, or the
addition of novel therapies that may
overcome the resistance observed.5-7,21-23
Results from various completed and
ongoing studies investigating alternate
treatment strategies to carboplatin þ
paclitaxel should be referenced when
considering treatment different than
carboplatin þ paclitaxel.3,5-7,8-10,21-23
In addition to identifying platinum-
resistant patients, the current study also
demonstrates the ability of the chemo-
response assay to generally identify
agents to which a patient’s tumor is
sensitive. The results presented herein
show that >90% of patient tumors were
sensitive or IS to at least 1 of the 7 most
common agents utilized clinically to
treat EOC. More importantly, for those
tumors resistant to carboplatin, >50%
of them were identiﬁed to be sensitive or
IS to at least 1 other agent. These results
exemplify the ability of the assay to
inform treatment decisions beyond the
carboplatin/paclitaxel standard of care.
These ﬁndings are also consistent with
those from a recent prospective study of
patients with recurrent EOC who
demonstrate an improvement in both
PFS and OS when treated with an assay-
sensitive therapy compared to those
treated with a nonsensitive agent,11
highlighting the clinical value of this
assay for individualized treatment of
EOC.
In summary, the chemoresponse assay
evaluated herein is independently asso-
ciated with PFS and may be used torican Journal of Obstetrics& Gynecology 68.e6
FIGURE 4
Distribution of assay results across 7 single-agent treatments
Patients (n¼ 153) were categorized as resistant to all 7 treatments (R7), intermediate or resistant to
all 7 treatments (I/R), or sensitive to anywhere from 1 (S1) to 7 (S7) treatments. Single-agent
treatments were: carboplatin, cisplatin, pegylated liposomal doxorubicin, gemcitabine, paclitaxel,
docetaxel, topotecan.
Krivak. Chemoresponse assay for platinum resistance. Am J Obstet Gynecol 2014.
Research Oncology www.AJOG.orgpredict platinum resistance in patients
with advanced-stage EOC prior to
treatment. Patients predicted for poorer
outcome (ie, platinum resistance) by the
assay (and in conjunction with other
clinical factors) may be considered for
investigation of alternate treatment
options. -REFERENCES
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